aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Average Rating of “Hold” from Brokerages

aTyr Pharma, Inc. (NASDAQ:ATYR) has earned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $23.25.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of aTyr Pharma in a research note on Monday, December 29th.

aTyr Pharma Price Performance

aTyr Pharma stock opened at $0.90 on Tuesday. aTyr Pharma has a 12 month low of $0.64 and a 12 month high of $7.29. The stock has a market capitalization of $88.09 million, a PE ratio of -1.08 and a beta of 0.59. The business has a 50 day simple moving average of $0.76 and a 200-day simple moving average of $2.01.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.06). The company had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.91 million. On average, equities research analysts anticipate that aTyr Pharma will post -0.91 EPS for the current fiscal year.

Institutional Trading of aTyr Pharma

Institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System acquired a new position in aTyr Pharma in the 2nd quarter valued at $28,000. Ameritas Investment Partners Inc. acquired a new position in aTyr Pharma during the second quarter worth about $45,000. Legal & General Group Plc acquired a new stake in aTyr Pharma in the 2nd quarter valued at about $49,000. Prudential Financial Inc. purchased a new position in aTyr Pharma in the 2nd quarter worth approximately $63,000. Finally, Oxford Asset Management LLP acquired a new position in shares of aTyr Pharma during the 2nd quarter worth approximately $70,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.